CAR T-Cell Therapy and Multiple Myeloma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 1666
Special Issue Editor
Special Issue Information
Dear Colleagues,
As in many cancers, immunotherapy is revolutionizing the treatment of multiple myeloma (MM). MM is characterized by the clonal proliferation and accumulation of malignant plasma cells in bone marrow. Although therapeutic advances have been made, there is a high, unmet therapeutic need regarding this relapsing disease. To address this clinical need, potent immunotherapies have been developed and consist of monoclonal antibodies, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T-cells (CAR-T). Different parameters such as T-cell fitness, the number of previous treatment lines, disease aggressiveness and disease extension may predict the efficacy of these treatments. CAR-T therapy is the most potent anti-myeloma treatment, but its clinical application is limited by its high costs, restricted access, and potential side effects.
This Special Issue welcomes research articles and review articles, from preclinical to clinical studies, in the field of CAR-T development and ways of improving their cytotoxic effects while limiting their side effects.
Dr. Jo Caers
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- CAR-T immunotherapy
- toxicity
- efficacy
- tumor models
- safety
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
